If you want to know what truly sets Dr. Isaac Eliaz apart, just ask Bonnie Bell, a spirited survivor of Stage 4 breast cancer, who experienced a near-miraculous recovery-one that most conventional doctors would have called impossible. But with Dr. Eliaz' guidance, her passion for life prevailed-and what was once considered an "incurable" diagnosis became another inspiring example of triumph over a deadly of diseases.

Today, Bonnie is alive, well, and in full remission. And like so many of Dr. Eliaz' patients, she attributes her healing not only to the strength of mind and body that she has found though her struggle, but also to the carefully integrated holistic protocol that led her there-an approach to fighting her disease that embraced both modern Western medicine and the centuries-old traditions of ancient healing wisdom.

This unique synergy is the heart of Dr. Isaac Eliaz' practice-and Bonnie is just one of many patients at Amitabha Medical Clinic and Healing Center to have faced death and lived to tell their remarkable stories. A respected author, lecturer, researcher, product formulator, and clinical practitioner, Dr. Eliaz has been a pioneer in the field of integrative medicine for over twenty years now-and his contributions to the growing body of research on natural cancer treatment have been profound.

Among these many contributions is his discovery of modified citrus pectin (MCP)-a substance derived from the peel of citrus fruit that has proven to be one of the most promising breakthroughs in integrative oncology to date. Not surprisingly, it was also an integral part of Bonnie Bell's treatment.

Research has revealed that cancerous cell communications are dependent upon a class of sticky cell surface proteins called galectins-a primary target in the search for new and effective cancer therapies. If these galectins can be bound and their communication cut off, then the growth and spread of cancer will be essentially disarmed. MCP is a modified form of ordinary citrus pectin, altered by means of a cutting-edge enzymatic process to meet the ideal size and molecular weight necessary for precisely this type of cancer inhibition.

Dozens of published studies in the past decade have been devoted to revealing the immense potential of this simple substance against a variety of cancers, including lung cancer, breast cancer, skin cancer, and prostate cancer. And the latest study provides some of the most compelling results so far.

Researchers at Albert-Ludwigs University in Freiburg, Germany enrolled 49 patients, each with advanced state solid tumors of varying types-colon cancer, prostate cancer, breast cancer, kidney cancer, lung cancer, cervical cancer, liver cancer, and pancreatic cancer, among others. Each patient had completed conventional treatments, including surgery, chemotherapy, and radiation without success-nearly 90 percent of the cancers had metastasized.

During the trial, patients were administered 5 grams of MCP orally, three times a day. They would later be evaluated for clinical benefit-including pain reduction, improved physical functioning, increased appetite and sleep, and reduced fatigue. At just eight weeks, the results were already overwhelmingly positive, with 20.7 percent of the patients showing an overall clinical benefit response and stabilization of disease. The results for those completing 16 weeks of treatment showed an overall clinical benefit of 42.9%.

Perhaps most remarkably, one patient with advanced hormonal refractory metastasized prostate cancer demonstrated a 50 percent decrease in PSA levels after 16 weeks, accompanied by a significant increase in clinical benefit. By the conclusion of the study, response rates continued to improve, with a majority of the patients showing improved quality of life and pain reduction.

Meg Jordan, health journalist and professor of Integrative Health and Medicine at the California Institute of Integrative Studies, says Dr. Eliaz's methods allow the body's innate healing mechanisms to be supported. "If cancer is our immune systems failing to detect cancer cells and sweep them out of our body, then allowing our immune systems to do their job with more efficiency and greater surveillance is suddenly a noble undertaking." It's the opposite of chemotherapy and radiation, which act like a big hammer and a poison, taking a toll on our bodies.

Nutraceutical is a new word referring to the wise use of nutrients in an action that is almost pharmaceutical-like within the body. Like Vitamin C, nutraceuticals, such as Bilberry extract, are derived from botanicals and sold without a prescription.

"In the laboratory we watch closely what happens with the nutraceutical in a cellular reaction," said Jordan. "The beauty is, what we see in the lab is so positive that going ahead and recommending their use to the general public generally has no downside."

"We are at a tipping point now, as the evidence builds in the labs as to what these botanicals can do, and we try to educate conventional doctors," Jordan explains.  "If we're erring, we are erring on the side of precaution, by suggesting people replicate what is happening in the laboratory."

Dr. Eliaz would be the first to note that these impressive results don't constitute a cure for cancer. But it is a major leap in the right direction, yielding benefits in this group of patients that were comparable to, if not better than, chemotherapy-without the adverse side effects or toxicity. The potential of MCP as part of an integrated and comprehensive approach to treating cancer is undeniable to many who've studied it-and the medical community at large is taking notice.

Dr. Stephen Strum, an oncologist who has devoted his practice and research to the treatment of prostate cancer, is among MCP's greatest advocates. "My clinical experience using MCP (modified citrus pectin) in prostate cancer," he says, "has been that it slows PSA doubling time in the majority of patients taking the standard dose of 5 grams three times per day."

"Because this treatment is well tolerated," he continues. "I use MCP in any situation where sustained increases in PSA may occur."

Dr. Eliaz founded EcoNugenics in 1995 to deliver nutraceuticals to the general public beyond his practice. Meg Jordan sees value in offering these products for sale over the web to patients far and wide.

"I just got a call from my dear friend just diagnosed with an aggressive form of breast cancer and I'm going to make sure she gets on it," explained Jordan. "She is going to take it to her oncologist and show them the research, saying she'd like to be on it as well."

For more information, visit EcoNugenics at www.econugenics.com.